Pontus Hedberg, Suzanne Desirée van der Werff, Pontus Nauclér
{"title":"接种 COVID-19 疫苗对 COVID-19 后遗症风险的影响:队列研究","authors":"Pontus Hedberg, Suzanne Desirée van der Werff, Pontus Nauclér","doi":"10.1093/infdis/jiaf133","DOIUrl":null,"url":null,"abstract":"We conducted a population-based cohort study in Stockholm, Sweden, to investigate the effect of COVID-19 vaccination on the risk of developing persistent PCC in individuals surviving the first year after a SARS-CoV-2 infection. 331,042 individuals were included, of which 852 had persistent PCC. The adjusted RR (95% CI) for developing persistent PCC compared with unvaccinated individuals was 0.81 (0.59-1.10) for 1 dose, 0.42 (0.35-0.52) for 2 doses, and 0.37 (0.27-0.52) for three doses. Reduced risks for vaccinated individuals were also observed when restricting the analyses to pre-Omicron and Omicron, as well as all subgroups including sex, age, and previous infection.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"16 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of COVID-19 vaccination on the risk of persistent post COVID-19 condition: Cohort study\",\"authors\":\"Pontus Hedberg, Suzanne Desirée van der Werff, Pontus Nauclér\",\"doi\":\"10.1093/infdis/jiaf133\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We conducted a population-based cohort study in Stockholm, Sweden, to investigate the effect of COVID-19 vaccination on the risk of developing persistent PCC in individuals surviving the first year after a SARS-CoV-2 infection. 331,042 individuals were included, of which 852 had persistent PCC. The adjusted RR (95% CI) for developing persistent PCC compared with unvaccinated individuals was 0.81 (0.59-1.10) for 1 dose, 0.42 (0.35-0.52) for 2 doses, and 0.37 (0.27-0.52) for three doses. Reduced risks for vaccinated individuals were also observed when restricting the analyses to pre-Omicron and Omicron, as well as all subgroups including sex, age, and previous infection.\",\"PeriodicalId\":501010,\"journal\":{\"name\":\"The Journal of Infectious Diseases\",\"volume\":\"16 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Infectious Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/infdis/jiaf133\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/infdis/jiaf133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The effect of COVID-19 vaccination on the risk of persistent post COVID-19 condition: Cohort study
We conducted a population-based cohort study in Stockholm, Sweden, to investigate the effect of COVID-19 vaccination on the risk of developing persistent PCC in individuals surviving the first year after a SARS-CoV-2 infection. 331,042 individuals were included, of which 852 had persistent PCC. The adjusted RR (95% CI) for developing persistent PCC compared with unvaccinated individuals was 0.81 (0.59-1.10) for 1 dose, 0.42 (0.35-0.52) for 2 doses, and 0.37 (0.27-0.52) for three doses. Reduced risks for vaccinated individuals were also observed when restricting the analyses to pre-Omicron and Omicron, as well as all subgroups including sex, age, and previous infection.